Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 67

recruiting
3 987
countries
28
conditions
2 109

951 trials match your criteria

Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ponsegromab

Study on the Effects of AR1001 (Mirodenafil Dihydrochloride) for Patients with Early Alzheimer's Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Mirodenafil Dihydrochloride

Psoriasis

Not recruiting

Study on the Safety, Effectiveness, and Blood Movement of Bimekizumab in Adolescents with Moderate to Severe Plaque Psoriasis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Bimekizumab

Dermatitis atopic

Not recruiting

Study on the Safety and Effectiveness of ADX-914 for Patients with Moderate to Severe Atopic Dermatitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bempikibart

Asthmatic crisis

Not recruiting

Study on the Effects of Verekitug (UPB-101) for Adults with Severe Asthma

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Human IgG1 kappa monoclonal antibody against CRLF2

Adenocarcinoma gastric+1

Not recruiting

Study of Pembrolizumab with Chemotherapy for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Study Comparing Ponatinib and Imatinib with Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib

Study on Mavacamten for Adults with Non-obstructive Hypertrophic Cardiomyopathy

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten

Myelofibrosis

Not recruiting

Study Comparing Fedratinib with Drug Combination for Myelofibrosis in Patients Previously Treated with Ruxolitinib

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan

Bladder cancer

Not recruiting

Study Comparing TAR-200 and Chemotherapy for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer After BCG Treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin

Hidradenitis

Not recruiting

Study on the Long-Term Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide

Study Comparing Subcutaneous and Intravenous Isatuximab with Pomalidomide and Dexamethasone for Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:65+ years
  • Substances:Dexamethasone
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.